

2021 Annual Report



HERE TO HEAL
Committed to healing the nation



Our Guiding Philosophy



WHO WE ARE

Our purpose at Jenburkt Pharmaceuticals Ltd. is to serve those in need of quality healthcare by bringing revolutionary, life-changing therapeutic solutions that are accessible to all. We believe in serving our patients - through them we serve God, Humanity and Nation.

MISSION

We wish to serve our patients, through them serve God, Humanity and Nation. Nothing gratifies us more than bringing a smile to our patients' face.

VISION

To instill trust in life sciences through delivering excellence by weaving together in-depth research, efficient use of resources and capital and unparalleled knowledge to build speciality, high-quality pharmaceutical formulations and healthcare products that bring positive change and health safety to families around the world.



SERVING THE NATION IN THE TIME OF NEED

2020 was an extraordinary year by any measure with COVID-19 enveloping us all in dread and despair.

Watching the number of cases rise steeply in India, all of us at Jenburkt were sincerely focused on what we, as a pharmaceutical company with a rich history of giving back and innovation, could do to truly serve our nation at this time of dire need.

This is why - in July 2020, Jenburkt became the second in the country to announce the launch of antiviral drug Favipiravir (brand name Favivent™) for the treatment of mild to moderate COVID-19 symptoms at the most affordable price, at that time, of Rs. 39/- per tablet.

Not just was this covered exceedingly favourably by mainstream media and regional news outlets, the public championed

Favivent and our conscious effort to keep the price reasonable to ensure maximum access. In fact, our competitive pricing set the tone for a price war with the industry incumbent, and paved the path for affordable pricing for others in the market - not just for the 200mg variant, but also 400mg & 800mg. We went a step ahead and even appreciated the affordable pricing of the product launched by a competing brand on social media - a move that was appreciated deeply by the public.

In the past one year, we have distributed packs of Favivent across the worst-hit cities in India and contributed to the recovery of thousands of patients and families across the country.

We went a step ahead and also donated INR 72 Lacs + worth of the medicine to certified health institutions, listed Favivent stock availability on our new-website so individuals had real-time visibility per city and also deepened our relationships with India's most experienced doctors in the field via a Knowledge Series of webinars.

We are incredibly proud of what our company and our exemplary team members around the world achieved, collectively and individually this past year, staring bravely in the face of the greatest health threat looming over us.

Just as our heart goes out to everyone affected by COVID-19, we bow our heads in gratitude to our first responders and medical professionals who are risking their lives every single day to keep us safe. They are the true heroes of this crisis, and their intrepid actions are an inspiration to us all at Jenburkt.

- We are proud to share that we are the **second in India** to introduce **high-quality antiviral Favipiravir (brand name FAVIVENT)** for mild to moderate COVID-19 symptoms.

- Manufactured at a US-FDA and EDQM compliant plant with the strictest safety and manufacturing protocols in place.

LAUNCHED AT A VERY AFFORDABLE PRICE TO SERVE THE NATION IN THIS TIME OF NEED!

Rs. 39 / tablet

**For the use of a registered medical practitioner only.*



In July 2020, we launched **FAVIVENT** (antiviral drug Favipiravir) for mild to moderate COVID-19 symptoms at a very affordable price of **MRP Rs. 39/tablet** to **serve the nation!**



*Prescription-only Medicine to be administered in prescribed dosage under a certified medical practitioner's supervision. For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory only.

WE WON

THE AWARD OF PHARMA EXCELLENCE 2020
for Covid Medical Education Initiatives!



"Given the current scenario of grave health concerns and economic challenges surrounding COVID-19 in India, if we as a pharmaceutical company cannot make a significant positive difference to the society, our company's very existence is inconsequential"

Mr. Ashish U Bhuta
Chairman and MD
Jenburkt Pharmaceuticals Ltd

Our continuous efforts to **serve the nation** by launching **Favivent** at Rs. 39/tablet at this time of need, and educating doctors across the country on Favipiravir are being recognized! Thank you for supporting us!



Excellent Quality with Affordable Price

PROUDLY INTRODUCING

Favivent

Favipiravir 200 mg Tablets

Vents out COVID-19.. **Effectively**

For adults with mild-to-moderate **COVID-19**

Price = Rs.39 per tablet

Manufactured at a   Manufacturing plant

*DCGI Approved oral antiviral in Mild to Moderate COVID -19



Dr Ivary ramuk @ivark2008 . 4d

@JenburktPharma thank you lot for your effort to release covid drug at reasonable price. This shows you are more people friendly and money conscious at these tough times



biswajit dash @Ar_BiswajitDash . 5d
Replying to @snehamordani
@jenburktPharma and @CNNnews18

good going guys... keep up the place..entire country will proud of you..



Dr Deepali Bhardwaj
@dermatdoc

Excellent news tablet **#favivent** Rs39/- announced by Company called jenburkt which gave a jolt to **#fabiflu** priced at 75/- by **#GLENMARK** so Cost of **#Covid_19** therapy comes down from 13-14k to half in India **#COVID19_BREAKING** Hoping everyone should get access to possible treatments.



Satyendradev Mahanti
@MahantiSd

Excellent move by Jenburkt.

PRODUCT LAUNCH MEDIA COVERAGE

The Favivent product launch has been covered by close to 100 publications across the country in just a few days of launch!

Business Today **Business Standard** **FINANCE REWIND** **NewsrapIndia**

live mint **NEWS 18** **LATESTLY** **INDIA TV**

INVENTIVA **UNI** **United News of India** **THE HINDU**
BREVITY ACCURACY SPEED India's Multi Lingual News Agency INDIA'S NATIONAL NEWSPAPER SINCE 1878

FINANCIAL EXPRESS **Business Today** **BW BUSINESSWORLD**
Read to Lead

EQUITY B BULLS **The New York Times** **DH DECCAN HERALD**

GSTV **yahoo! news** **GO INDIA NEWS** **asianet news हिन्दी**
देश की धड़कन

NA **पंजाब केसरी** **Newzz** **SME STREET** **ZOOM News**
Latest news from trusted sources

ZEE २४ घण्टा **CG TOP 36** **GLOBAL FINANCIAL MARKET REVIEW**
www.cgtop36.com Only Sense, No Nonsense

NDTV PROFIT **WION** **The WB Mirror**

We've gone digital!

We are delighted to announce that we have launched an all-new website and are now active on leading social media platforms!

FOLLOW, LIKE & SHARE

www.jenburkt.com


info@jenburkt.com

[+91 22 67603603](tel:+912267603603)

[in](https://www.linkedin.com/company/jenburkt) [f](https://www.facebook.com/jenburkt) /jenburkt

[ig](https://www.instagram.com/jenburktpharma) /jenburktpharma

[YouTube](https://www.youtube.com/channel/UC...) bit.ly/JenburktYoutube




Making It Easier to Get Affordable, Life-Saving Medications to Patients Across India with SAP S/4HANA



At Jenburkt, our Intent and Focus is on **processes and adopting** Technology across all departments.

We have reliable System driven processes set up and adopting the latest technology like the latest version of SAP S/4HANA and SAP BusinessObjects business intelligence solutions. We have benefited from their tight, native integration between processes, industry depth, and a consistent in-memory data model.

We have used these digital tools to simplify complex processes and improve operational efficiency and visibility, especially in batch-tracing and inventory management. Additionally, it has helped us analyze sales and performance by product and region for medical representatives across the country.



In the past year, a case study on our usage of SAP S/4 Hana featured on the SAP global website as well as their social media channels.

Founders

Board of Directors

Company Secretary

Auditors

Bankers

Registered Office

Plant

Research & Development Centre

Registrar & Transfer Agents

Index



Notice
